Axiom Biosciences targets $200M Hong Kong IPO in 2027, then US listing in 2029
The newborn-brain-injury biotech is betting on Hong Kong capital markets before a later US secondary listing.
By Hessa Al-Faleh·· 3 min
Loading the Newsroom
Curating from trusted global sources…